Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7103229 | 0.92 | MEN1 (0.50) | MEN1KMT2AMAPK1RAB9ANPC1 | |
| SCHEMBL7103712 | 0.83 | KMT2A (0.50) | MEN1KMT2AMAPK1ALDH1A1POLB | |
| SCHEMBL7103714 | 0.82 | KMT2A (0.49) | MEN1KMT2AMAPK1ALDH1A1POLB | |
| SCHEMBL7099648 | 0.82 | MEN1 (0.49) | MEN1KMT2AMAPK1ALDH1A1LMNA | |
| SCHEMBL7098125 | 0.82 | KMT2A (0.49) | MEN1KMT2AMAPK1ALDH1A1POLB | |
| SCHEMBL7023002 | 0.82 | LMNA (0.41) | MEN1KMT2ARAB9ALMNASMN1; SMN2 | |
| SCHEMBL7026359 | 0.79 | LMNA (0.38) | MEN1KMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL5155067 | 0.78 | MEN1 (0.43) | MEN1KMT2AMAPK1RAB9ANPC1 | |
| SCHEMBL6333401 | 0.78 | MMP1 (0.44) | MEN1KMT2ARAB9AALDH1A1POLB | |
| SCHEMBL5157345 | 0.76 | MEN1 (0.44) | MEN1KMT2AMAPK1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030224940-A1 | Alpha-sulfin-and alpha-sulfonamino acid amide derivatives | SYNGENTA CROP PROTECTION, INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1272461-A1 | ALPHA-SULFIN- AND ALPHA-SULFONAMINO ACID AMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001079160-A1 | ALPHA-SULFIN- AND ALPHA-SULFONAMINO ACID AMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030224940-A1 | Alpha-sulfin-and alpha-sulfonamino acid amide derivatives | STS, ARSA, SULT2A1 | MEN1 2787/4885KMT2A 1753/4885MAPK1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.